As Featured In
Bespoke Sector Analysis
May 6, 2020
February 4, 2019
[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
October 24, 2018
[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
October 10, 2018
[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong third quarter, with over $3.18B raised by 26 companies across the globe, bringing the year-to-date total up […]